







Objectives:

1st Renal System:

- 1. Upper Urinary Tract (Kidney And Ureter)
- Renal Tumors
- Benign Tumors
- Nephroblastomas (Clinical Features, Investigations, Management)
- Renal Adenocarcinoma (Clinical Features, Investigations, Management)
- Transitional Cell Carcinoma Of The Upper Tracts.
- 2. Lower Urinary Tract (Bladder, Prostate And Urethra)
- Bladder Tumors (Pathology, Staging, Clinical features, Investigations, Management and Prognosis)
- Carcinoma Of The Prostate (Pathology, Clinical features, Investigations, Management and Prognosis)

3. External Genitalia:

- Testicular Tumours
- Carcinoma Of The Penis

2nd Adrenal Medulla:

Phaeochromocytoma (Pathology, Clinical features, Investigations, Management)

Sources: Slides, Principles & Practice of Surgery by: O. James Garden

Color Index: Slides | Textbook | Doctor's Notes | Extra Explanation

1st: Renal Tumors

1- Malignant Tumors

- Most renal tumor are malignant (benign are rare), and more common in male (2:1 ratio).
- Uncommon before the age of 40 years and has a peak incidence between 65 and 75 years of age.
- Most renal tumor arise from proximal tubule cells.
- Like to invade **veins** (renal vein, IVC).
- ► Commonest histopathological tumor in kidney is Clear Renal Cell Carcinoma (A.K.A Hypernephroma or Grawitz tumor)
- Most renal tumor are sporadic, it can be familial like; <u>VHL syndrome</u>¹.
- Hematogenous spread is most common, and the Commonest site for metastasis is the lungs.

* Clinical Presentation:

- 10% of patient come with triad of: Hematuria, loin pain, palpable mass*
- Some patient present with: Paraneoplastic Syndrome².

• Others present with: 1- Hyperyetnsion, 2- Pyrexia (fever) of unknown origin, 3- Polycythemia: (due

to **1** of erythropoietin)

4- Hypercalcemia:

(due to production of PTH-like Hormone)

- 5- Increased ESR³.
- 6- Disorders of coagulation.
- 7- Abnormalities of plasma proteins.
- 8- Abnormalities of Liver Function Tests.
- 9- Neuromyopathy.



Cannonball appearance in pulmonary metastasis

Microscopic appearance of Clear Renal Cell Carcinoma

- (1) Von Hipple-Lindau Syndrome: Mutation of VHL gene in short arm of chromosome <u>3</u>, it's Autosomal dominant, associated with renal cell carcinoma, renal-hepatic-pancreatic-epididymal cysts, pheochromocytoma, angiomatosis and hemangioblastomas. When suspected, bring the whole family for screening.
- (2) ParaNeoplastic Syndrome: A unique feature of renal cancer, and the tumor starts secreting hormones e.g. ADH or EPO.
- * Nowadays it disappear due to earlier diagnosis due to ultrasound. (3) Erythrocyte Sedimentation Rate

* Investigation



1-Ultrasound


(Initial + confirmetive)

2- CT contrast of abdomen and chest

- allows assessment of renal vein and caval spread (IVC)
- •It is used for staging



igure 1: Computed tomography scan atient's chest when he was first diagnosed with tracardiac extension of disease.



3- Echocardiogram

 should be considered if clot in IVC extends above diaphragm

2- Benign Tumors

- Renal adenomas are small and are usually an incidental finding.
- Haemangiomas are a <u>rare cause</u> of dramatic haematuria.



- 1 Open Radical Nephrectomy (Sart at 1:00)
- (2) <u>Laparoscopic Nephrectomy</u>
- 3) what's Immunotherpy?

*** Management:** the only choice is surgery



1-Open Radical Nephrectomy


- Kidney and adjacent tissue (adrenal, perinephric fat) excised (in both open and laproscopic Nephrectomy)
- (big scar, more pain especially with respiration)

2- Laparoscopic Nephrectomy

(Gold Standard)

- Groin Incision (muscle splitting incision): to avoid cutting through muscle.
- Transvaginal Approach: For post-menopausal women who have undergone hysterectomy
- (Advantages: smaller scar, Less pain)





3- Immunotherapy

- Monoclonal antibodies, interferon, cytokine inhibitors and tyrosine kinase inhibitors.
- Very cytotoxic. Given only to patients with good performance status
- •Not curable but it can prolong his life for 6-8 months
- In case of metastasized

Chemo and Radiotherapy

- Kidney tumors are **resistance** to both.
- Indicated In: cases of symptomatic bone metastasis, in order to relieve pain



Renal Tumors in Children (From the textbook)

3- Nephroblastoma: (A.K.A. Wilm's Tumor)

- The most common childhood urological malignancy
- occurs in children under 4 years.
- Very rapid growth with early local spread including Renal Vein.
- Distant metastasis including: liver, lung and bones.
- Bilateral in 5-10% of cases.

* Clinical Featurs:

- Large abdominal mass. And unusally, fever and hypertension may present.
- ---> Hematuria only present in 15% of cases.
- ---> The affected child is not gaining weight and not playing (الطفل خامل)
- ---> Clinically it needs to be differentiated from **Neuroblastoma**

* Investigation:


- O CT of the abdomen and chest : for diagnosis and staging.
- O Diagnosis is confirmed by biopsy.

* Management:

- Chemotherapy, followed by transabdominal Nephrectomy with wide excision of the mass.
- **Operative:** Further chemotherapy ± Radiotherapy.

4- Neuroblastoma: (See the table)





| Table 23.2 | Childhood renal tun | nours |
|----------------------------|---|---|
| Feature | Nephroblastoma | Neuroblastoma |
| Frequency | MC childhood tumour of renal origin | MC extracranial solid malignant childhood tumour |
| Age | Between 3–5 years of age | < 2 years of age |
| Origin | Kidney | MC adrenal, also extra-adrenal |
| Symptoms | Hypertension in 25–60% | Uncommon |
| Abdominal lump | Unilateral, never crosses midline | May cross midline |
| Radiologically | No change in renal axis | Outward and downward displacement of kidney; calcification common |
| Metastases at presentation | Uncommon | Bony metastases common |
| Tumour markers | Serum LDH may be raised | VMA may be raised |
| Treatment | Surgery mainstay, adjuvant chemotherapy for metastases | Chemotherapy, radiotherapy and surgery |

2nd: Bladder Tumors (BT)

Like kidney, most of bladder tumors are malignant.

Transitional
Cell
Carcinoma
(90%)

***** Pathology:

- Risk Factor:
- Smoking
- chemical exposure
- analgesic abuse (phenacetin)
- Occupational Exposure(~20%):
 Chemical implicated: aniline dyes,
 chlorinated hydrocarbons.

Superficial and well differentiated: (80% of TCCs)

- Above the muscle layer (muscularis propria)
- Only 20% progress to muscle invasion
- Associated with good prognosis, but higher recurrence rate (50%)

Deep, high-grade & muscle invasive: (20% of TCCs)

- 50% have muscle invasion at time of presentation.
- Associated with poor prognosis

(5%) Adenocarcinoma

(2%)

Squamous Cell

Carcinoma

* Risk Factors:

Chronic irritation (e.g. UTI, Stone, catheter, Bilharziasis* "Schistosoma haematobium")

Risk Factors: Crohn's disease, Urachal remnant abnormalities

✓ Other Risk factors: Pelvic irradiation - for carcinoma of the cervix

***** Clincal Presentation:

- 80% present with Gross Painless Terminal Hematuria* It should be assumed that such bleeding is from a tumor until proved otherwise.
- Also, present with **treatment-resistant infection** or bladder irritability and sterile pyuria (other DDx: TB)
- If the tumor involved the ureteric orifice → obstructive symptom .
- Patient with **UTI resistance** to treatment \mapsto think of <u>tumor</u>.

*Common in Jizan

^{*}Haematuria Classification: indicate the site of problem. initial hematuria (urethral), terminal hematuria (trigone of bladder, prostate), total hematuria (bladder, ureter, kidney)

***** Staging:

- **Biopsy:** (Requires bladder muscle to be included in specimen)
 - is essential to: confirm the diagnosis (cell type), determine the degree of cell differentiation (grade) and Assess the depth to which the tumor has penetrated the bladder wall (stage).
 - It gives accurate information on **superficial tumors**, but depth of invasion of invasive tumors cannot be assessed precisely (as the biopsy does not examine the full thickness of the bladder wall).
- The TNM system of tumor classification:

Well differentiated

Poorly differentiated


Moderately well differentiated

G1

G2

G3

- 1- Assessment of The Primary Tumor (T): requires bimanual examination under anesthesia (important, especially for T2 and T3)
- 2-Assessment of The Involvement Of Regional And Juxtaregional Lymph Nodes (N): By Clinical examination, urography and CT.
- **3- Assessment of Distant Metastases (M)**: By clinical examination and CT.
- Histo-Pathological Examination: to guide the choice of treatment.



| Staging: according to depth of tumor invasion | | |
|---|-----|-----------------------------|
| cial | Tis | In-situ disease |
| Superficial | Ta | Epithelium only |
| Sup | T1 | Lamina propria invasion |
| a) | T2 | Superficial muscle invasion |
| sive | T3a | Deep muscle invasion |
| Invasive | T3b | Perivesical fat invasion |
| | | |

Prostate or contiguous muscle


T4


★Investigation:
















KUB = Kidneys,
Ureters, and
Bladder

★ Carcinoma In-situ

- Carcinoma-in-situ is an aggressive disease
- Often associated with positive cytology
- 50% patients progress to muscle invasion
- Consider immunotherapy
- If fails patient may need radical cystectomy




* Management:

Intravesically = they are put directly into the bladder through a catheter.

²BCG = attenuated strain of Mycobacterium bovis

1) For Superficial Bladder Tumors (Ta,T1):



1- TransUrethral

Resection of the

Blabber Tumour


(TURBT)


• The ideal choice




- Prophylactic: if risk factor for recurrence or invasion (e.g. high grade). High risk: 1.Multiple tumors 2. Big tumors 3.Carcinoma in situ
- **Used For**:multiple low-grade bladder tumors.









3- Immunotherapy

- →intravesical Bacille Calmette Guérin(BCG)²
- •Used to: Reduces risk of recurrence and progression.
 And for Carcinoma in situ
- Occasionally, associated with development of systemic mycobacterial infection

4- Cystectomy


 If Recurrences become very frequent and excessive

Cystoscopy

- For follow-up
- To watch out for recurrence due to the high recurrence rate of superficial TCC


2) For Invasive Bladder Tumor (T2–T3s):

- 1- Radical Cystectomy: (Local recurrence rates = 15%)
- It's the removal of bladder, prostate, distal ureter and lymph nodes and In females: also the uterus, cervix and anterior vaginal wall
- Treatment of choice for patients under 70 years of age.
- **2- Radiotherapy**: (Local recurrence rates = 50%)
- Alone, in patients **older than** 70 of age.
- Not needed Pre-operativly.
- **3- Chemotherapy:** Adjuvantly, it may have a role.




Ileal conduit

(most common one) reservoir
(incontinent diversion to skin) (Continent diversion to skin)



Types of Urinary Diversion:


Continent cutaneous reservoir



Orthotopic neobladder (Continent diversion to urethra)

3rd: Prostate Tumors

- It's the commonest malignancy of male urogenital tract.
- Usually between the age 50-75. (A rare tumor of males under the age of 50).
- Found at post-mortem in 50% of men older than 80 years.
- 5-10% of operations for benign disease reveal unsuspected prostate cancer.




Pathology

- **Adenocarcinoma:** A slow growing malignant tumor originated from the glandular tissue of the **peripheral zone** (in 70% of cases) of the prostate.
- Very common in western countries. Rare in Japan and china
- The tumor itself is not lethal, but it can spread and cause serious manifestations, Patients die with the tumor not from the tumor.
- spread locally to the adjacent **perineal structures** (bladder neck, pelvic wall and rectum)
- Commonly spread through lymphatic especially to pelvic lymph. In 1/3rd of cases it already reaches the Regional Lymph Node at the time of presentation (Regional Lymph Node = a lymph node that drains lymph from the region around a tumor)
- 15% of cases show **bone metastases** (e.g. Lumbar spine and Pelvis) **through hematogenous spread.**

The tumor is usually asymptomatic. But if not, the patient may present with:

- **1- Acute Retention: in 25%** of patients, especially if the tumor size is large enough to narrow the urethra. (Although the tumor may not involve the transitional zone of the prostate, yet its presentation is similar to BPH)
- **2- Altered Bowel Habits:** If the tumor extend posteriorly around the rectum.
- **★** Metastatic Manifestations :
 - ✓ Back Pain, Spinal cord compression, Leukoerythroblastic Anemia and Leukopenia (♥ WBCs): all due to the involvement of bone marrow.
 - ✓ Weight Loss
 - Renal Failure: if the tumor obstruct both ureters.

Clinical Features



Diagnosis

In majority of patients, the diagnosis is made by screening (PSA)

Prostate Specific Antigen (PSA)

- A protein produced by prostatic epithelial cells.
- Normally, serum levels < 3.5 ng/ml (if less than 65 years of age) *and some say 4ng/ml*
- > 10 ng/ml highly suggests prostate cancer.
- > 100 ng/ml almost always indicate distant bone metastases.
- Not specific (Can also be raised in BPH).
- The main test for monitoring response to treatment and disease progression
- In 10% of cases, the tumor detected incidentally after Transurethral prostate resection in people with other prostatic diseases (e.g. BPH).

Investigations:




- to assess the any urinary tract obstruction.
- Locally advanced ones can be **confirmed** by the

examination alone

Findings: hard nodule or loss of central sulcus



 To Confirm the diagnosis



- 5-MultiParametric MRI*
- useful in the **staging** of the disease (although there are some interesting debates about its benefit)



6-Pelvic/ **lumbar** spine X-ray

- to investigate back pain
- May show osteosclerotic metastases



7-Bone Scan

•may be carried out at follow up to localize and define the **extent of** metastases



8- CT Scan

 is useful to assess pelvic lymphadenopathy.




*Multiparametric MRI of the prostate

Grading / Staging

Prostate cancers are graded using Gleason's Score:

- Gleason grading system is based on a histologic evaluation of prostate tissue samples.
- The Gleason score is the sum of the two most common cell patterns seen in the tissue sample. The patterns can range from 1 (well differentiated) to 5 (poorly differentiated, highly malignant).
- Over-all scores range from 2 to 10. A grade of 2 has the best prognosis, while a grade of 10 represents poorly differentiated tissue and confers the worst prognosis.
- Staging is done using **TNM** classification . (see the tables below)

Table 23.2 TNM classification of prostate cancer* T (Tumour) T₀ No evidence of primary tumour Primary tumour cannot be assessed Tumour clinically inapparent and not palpable Incidental finding following TURP in < 5% prostate chips • T_{1b} Incidental finding following TURP in > 5% prostate Prostate cancer detected by prostate biopsy Palpable nodule involving half of one lobe Palpable nodule involving one lobe Palpable nodule involving both lobes Extracapsular extension of prostate cancer Prostate cancer involving the seminal vesicles Prostate cancer involving the bladder neck and/or external sphincter and/or rectum • T_{4b} Prostate cancer involving the lateral pelvic wall N (Nodes) N₀ No regional lymph node metastasis N_v Regional lymph nodes cannot be assessed Regional lymph node metastasis M (Metastases) • M₀ No distant metastasis detected M_v Distant metastasis cannot be assessed Metastasis to non-regional lymph nodes Skeletal metastasis present Metastasis to other sites









Prostate Cancer: Gleason Score

Degree of

Spread

- **Treatment depends on:** stage of disease, patient's age and general fitness.
- The option of the treatment depends on the degree of spread:

Options

| | | 1- Observation | In patients with small focus of well- differentiated carcinoma |
|--|---------------------|---|--|
| Management | Local | 2- Radical Radiotherapy* 3- Radical Prostatectomy | In young patients In large tumors with a less well-differentiated cell pattern (Gleeson score 7 or more) |
| | Locally Advanced | Radical Radiotherapy (EBRT) and/or Hormonal Therapy | In cases where the prostate cancer has invaded directly outside the prostate but has not metastasized |
| | Metastatic | Androgen depletion Surgical Castration Luteinizing Hormone Anti-Androgens:- ex Complete Androgen Estrogen administra | ancers are androgen dependent for their growth. On can be achieved by: Bilateral Orchiectomy (removal of both testicles) Releasing Hormone (LHRH) Agonists:- example: Goseraline amples: Cyproterone Acetate, Flutamide and Biclutamide Blockade (using both LHRH Agonists and Antiandrogens) Ition. S: has shown improvement in both symptoms and survival |
| * Radical: a resection of the main organ along with the structures surrounding it. ✓ Prostatectomy can be done by: Open surgery, Laparoscopically or robotically. ✓ Radiotherapy can be performed using: 1- External beam Radiotherapy (EBRT): where The patient sits or lies on a couch and | | | |

an external source of radiation is pointed at a particular part of the body. 2- Intensity modulated RT (IMRT): a computer controlled

delivery of precise radiation doses to a malignant tumor or specific areas within the tumor

3- Brachytherapy: Insertion of radioactive seeds in the prostate.

Used In

4th: Testicular Tumors

- Commonest malignancy in young men (20-40 years old).
- → Highest incidence in Caucasians in Northern Europe and USA.
- ♦ 5 years survival rate is higher than 95% in localized tumors.
- ♠ Risk Factors: Cryptorchidism(Undescended testis), Testicular Maldescent, Testicular Torsion and Klinefelter's syndrome.
- ✦ However, Orchidopexy(Surgical fixation of an undescended testis in the scrotum) doesn't reduce the risk of developing testicular tumor.
- ♦ Metastases occur commonly through lymphatics, the tumor can also reach the lung hematogenously.

* Pathology:

| 1) Germ (| 2) Non Germ Cell | | |
|--|---|---|--|
| Seminomas | None Seminomas | Tumors | |
| Most Common. Arises from seminiferous tubules. Peak incidence 35 years old. Low grade malignancy. Radiosensitive, with cure rate 90%. Treatment depend on the stage of the seminoma | 1- Teratoma Arises from primitive germ cells. Peak incidence 25 years old. May contain bone, cartilage, muscles, fat and other tissues. Classified according to degree of differentiation. Chemosensitive. Radioresistant 2- Embryonal Carcinoma Yolk Sac Tumors Choriocarcinoma Mixed Germ Cell Tumor | 1- Malignant Lymphoma 2- Sertoli Cell Tumor 3- Interstitial Cell Tumors | |

Occasionally, Seminoma and teratoma occur in the same testis and account for 85% of testicular tumors

* Clinical Features:

- 1. Painless Lesion(testicular lump): discovered incidentally. (Most common presentation)
- 2. Swelling and Pain: suggesting inflammation, those patients may have wrongly received a treatment of acute epididymitis.
- **3. Gynecomastia:** in patients with **Teratoma** (Very **rare** presentation).
- **4. Hydrocele:** painless buildup of watery or blood fluid around one or both testicles.

***** Staging:

Accurate staging is based on Thoraco-Abdominal CT-scan. (of the lungs, liver and retroperitoneal area)

| Stage I | Disease Confined To Testis. |
|-----------|---|
| IM | Rising Post-orchiectomy Tumor Marker. |
| Stage II | Abdominal Lymphadenopathy (A <2cm - B 2-5cm - C >5cm) |
| Stage III | Supra-diaphragmatic Disease. |

| | | Table 2 | 23.4 Royal Marsden classification for testicular |
|---|---|---------|---|
| | • | Stage 1 | Tumour confined to testis |
| 8 | 0 | Stage 2 | Tumour spread only to lymph nodes below diaphragm |
| | • | Stage 3 | Tumour spread only to lymph nodes above and below diaphragm |
| | • | Stage 4 | Tumour spread to inguinal lymph nodes or distant metastases |

* Investigation

- 1- Testicular Ultrasound: to confirm the Diagnosis
- **2- Performing An Inguinal Orchiectomy**: to make a Pathological diagnosis
- **3- Tumor Markers:** are useful in staging and assessing response to treatment.
- But remember, The absence of the tumor marker doesn't exclude malignancy.
- ★ Markers include:
 - a) α-Fetoprotein: an indicator of yolk sac tumor. (Not produced by seminomas)
 - b) B-hCG (human Chorionic Gonadotropin): an indicator of trophoblastic elements such as Choriocarcinoma and Hyditiform mole it can also be elevated in Seminomas and Teratoma as well.
 - c) Lactate Dehydrogenase.
- 4- Ultrasound: for lungs, liver and peritoneum.
- 5- Assessment Of Renal And Pulmonary Function.

* Management:

| Tumor Type | Management | |
|--------------|--|--|
| Seminoma | Early stage (Stage I – IIB) → inguinal orchiectomy + Radiotherapy {to ipsilateral abdominal and pelvic nodes 'Dog leg'} Stage IIC and III → Chemotherapy. | |
| Non-Seminoma | Stage I → Orchiectomy Relapsed Stage I & Metastatic cases → Chemotherapy (Bleomycine, Etopiside, Cisplatin) | |

2 years follow-up by the three tumor markers and CT-scan is essential.

5th: Carcinoma of The Penis

- This uncommon tumor. It is **very rare in circumcised men** and almost always occurs in the **elderly.**
- The cancer may be a papillary or an ulcerating squamous cell carcinoma.
- Lymphatic spread to inguinal lymph nodes is common; associated infection may also lead to lymphadenopathy.
- * Clinical Features: The patient may present with a purulent or blood-stained discharge. Unfortunately, many patients do not seek help until the lesion is advanced.
- * Diagnosis: The diagnosis must be confirmed by biopsy.

* Treatment:

- **1-Circumcision:** may cure early tumors confined to the prepuce.
- **2- Excision Of The Glans And Skin Grafting :** in Early tumors confined to the glans.
- **3- Partial Or Total Penile Amputation With Bilateral Block Dissection Of The Inguinal Lymph Nodes:** required in Advanced tumors.
- **4- Radiotherapy:** for Inoperable tumors.

6th: Pheochromocytoma

- Are tumors originated either from the adrenal medulla (80%) or paraganglionic tissue (20%).
- Adrenal type secrete both Catecholamines while the latter secretes only norepinephrine.
- Can be associated with MEN-II syndrome, **Von Hippel-Lindau** disease **and neurofibromatosis**.

Clinical Features

★ Symptoms:

- Headache
- Palpitation
- Sweating
- Extreme anxiety
- Chest and abdominal pain.

★ Signs:

- Sever paroxysmal hypertension (200/100 mmHg).
- Pallor
- Dilated pupils
- Tachycardia.
- Mottled skin.
- Glycosuria.
- ✓ Sudden death after trauma and during surgery is common due to severe hypertension which can cause CVA.

Investigations

- ✓ Measurement of Urinary levels of Metadrenaline and Normetadrenaline.
- ✓ CT Scan
- ✓ MRI

Management

- ▶ Surgical removal of the tumor is the treatment of choice.
- \triangleright α and β -blocking drugs: are widely used in order to control the hypertension.



| Renal Tumors | Most renal tumor are malignant (benign are rare), and more common in male Commonest histopathological tumor in kidney is clear renal cell carcinoma Hematogenous spread is most common and the Commonest site for metastasis is lung Triad of symptoms: 10% of patient come with Hematuria, loin pain, palpable mass Some patient come with paraneoplastic syndrome Kidney tumors are resistance to chemo and radiotherapy, only choice is surgery "Radical nephrectomy" |
|-----------------------------------|--|
| Bladder Tumors | Like kidney, most of bladder tumors are malignant Usually patient come with Gross Painless Terminal Hematuria* In staging, T2 or more consider as deep, below T2 is superficial Patient with UTI resistance to treatment → think of tumor Treated be resection (radical cystectomy) with 10% mortality rate, + consider Immunotherapy. |
| Prostate Tumors (Prostate Cancer) | A slow growing malignant tumor originated from the glandular tissue of the peripheral zone of the prostate It's the commonest malignancy of male urogenital tract. It could spread locally to the adjacent perineal structures, causes acute retention and altered bowel habits. In majority of patients, the diagnosis is made by screening (PSA) Locally advanced ones can be confirmed by rectal examination. Treatment depends on stage of disease, patient's age and general fitness. |
| Testicular Tumors | Commonest malignancy in young men (20-40 years old) Most common risk factors include cryptorchidism. The tumors mostly discovered incidentally as it's a painless lesion. However, patients can present with swelling and pain. The Classification includes: Seminomas (~50%) Radiosensitive, Non-Seminoma (~50%) Radio-resistant Diagnosis can often be confirmed by testicular ultrasound. Tumor markers are useful in staging and assessing response to treatment like Alpha-fetoprotein, Beta HCG, Lactate Dehydrogenase |
| Pheochromocytoma | Adrenal type secrete both Catecholamines while the latter secretes only norepinephrine. Can be associated with MEN-II syndrome, Von Hippel-Lindau disease and neurofibromatosis. The patient presented with sever paroxysmal hypertension (200/100 mmHg). Investigations include Measurement of Urinary levels of metadrenaline and normetadrenaline, CT and MRI can show the tumor. Surgical removal of the tumor is the treatment of choice. |

Thank You...

Done By:

Abdulrahman Al-Thaqib
Maen Al-Herbish

Revised By:
Faisal S. Al-Ghamdi
Aisha AL-Raddadi
Amjad Abalkhail

